ReviewCurrent atherosclerosis reports2026
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2026 American College of Cardiology Conference.
Review in Current atherosclerosis reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo summarize key findings from cardiovascular disease prevention trials at the 2026 American College of Cardiology (ACC) Conference. RECENT
findingsThe Ez-PAVE trial demonstrated that targeting low-density lipoprotein cholesterol (LDL-C) levels < 55 mg/dL significantly reduces major adverse cardiovascular events compared with a target of < 70 mg/dL in patients with established atherosclerotic cardiovascular disease (ASCVD). A subgroup analysis of the VESALIUS-CV trial showed that Evolocumab reduced first cardiovascular events in high-risk individuals with diabetes who did not have known significant atherosclerosis. The CORALreef AddOn trial demonstrated the superior LDL-C-lowering efficacy of the oral PCSK9 inhibitor Enlicitide compared with ezetimibe, bempedoic acid, and the combination of the two. The Ez-PAVE trial demonstrated that targeting low-density lipoprotein cholesterol (LDL-C) levels < 55 mg/dL significantly reduces major adverse cardiovascular events compared with a target of < 70 mg/dL in patients with established atherosclerotic cardiovascular disease (ASCVD). A subgroup analysis of the VESALIUS-CV trial showed that Evolocumab reduced first cardiovascular events in high-risk individuals with diabetes who did not have known significant atherosclerosis. The CORALreef AddOn trial demonstrated the superior LDL-C-lowering efficacy of the oral PCSK9 inhibitor Enlicitide compared with ezetimibe, bempedoic acid, and the combination of the two. Imaging and diagnostic advances were highlighted by the GPS-CAD study, which demonstrated variability in the reliability of a coronary artery calcium score (CACS) of zero across diverse populations. In contrast, the Essence-TIMI 73b substudy found no significant impact of triglyceride lowering with olezarsen on coronary plaque progression over 12 months. Lifestyle and health equity-focused interventions, including the GoFreshRx and THRIVE trials, demonstrated meaningful reductions in blood pressure through dietary and food-as-medicine strategies in underserved populations. Additionally, the SURPASS-CVOT post hoc analysis showed that tirzepatide reduced composite cardiorenal outcomes compared with dulaglutide in patients with type 2 diabetes. Finally, the SMART-DECISION trial suggested that discontinuation of beta-blockers in stable patients one year after myocardial infarction with an LVEF of at least 40% may be safe and noninferior to continuation. The studies presented at ACC 2026 emphasize the importance of intensive lipid-lowering strategies, expand the use of new cardiometabolic therapies, and showcase emerging diagnostic and preventive strategies for ASCVD.
Indexed as
Identifiers
42142201What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.